Overview

An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with active ulcerative colitis (UC) (sores in the colon).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Antibodies, Monoclonal
Golimumab